Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Letters to the Editor

In Reply: 2023 Update in ambulatory general internal medicine

Jason T. Alexander, MD, Simran K. Singh, MD, Sachin D. Shah, MD, Brianna Lambert, MD and Jeremy P. Smith, MD
Cleveland Clinic Journal of Medicine March 2024, 91 (3) 146; DOI: https://doi.org/10.3949/ccjm.91c.03002
Jason T. Alexander
Department of Medicine, University of Chicago, Chicago, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simran K. Singh
Department of Medicine, Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sachin D. Shah
Department of Medicine, University of Chicago, Chicago, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brianna Lambert
Department of Medicine, University of Chicago, Chicago, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy P. Smith
Department of Medicine, University of Wisconsin, Madison, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

We appreciate Ashley Lim’s close read of our review. Regarding the use of SGLT-2 inhibitors in patients without albuminuria, as we point out, the EMPA-KIDNEY trial1 was the first large randomized trial of SGLT-2 inhibitors to enroll patients with chronic kidney disease without albuminuria. Two other large randomized trials of SGLT-2 inhibitors have evaluated patients with chronic kidney disease with or without diabetes, but both required some degree of albuminuria.2,3 Thus, we conclude that there is currently no convincing evidence to support using SGLT-2 inhibitors to prevent kidney disease progression in patients with chronic kidney disease without significant albuminuria. Given the higher rates of cardiovascular disease among patients with chronic kidney disease, managing cardiovascular risk (eg, reducing systolic blood pressure in patients with hypertension or initiating statin therapy)4 should be prioritized over initiating SGLT-2 inhibitors for these patients until such evidence emerges.

Regarding the feasibility of recommending a Mediterranean diet over a low-fat diet for secondary prevention of major cardiovascular events, we share Lim’s concern that many patients are not able to access, afford, or implement such a diet. Additional measures available to participants of the Delgado-Lista et al study,5 including individual and group appointments with dietitians both in person and by telephone, are also unlikely to be available to the majority of patients who may benefit from a Mediterranean diet. Despite these limitations, we found that this study provides important insights into dietary recommendations that clinicians may use when counseling patients with previous cardiovascular disease.

  • Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. The EMPA-KIDNEY Collaborative Group;
    2. Herrington WG,
    3. Staplin N,
    4. Wanner C, et al
    . Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388:117–127. doi:10.1056/NEJMoa2204233
    OpenUrlCrossRefPubMed
  2. ↵
    1. Heerspink HJL,
    2. Stefánsson BV,
    3. Correa-Rotter R, et al
    . Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15):1436–1446. doi:10.1056/NEJMoa2024816
    OpenUrlCrossRefPubMed
  3. ↵
    1. Perkovic V,
    2. Jardine MJ,
    3. Neal B, et al
    . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24):2295–2306. doi:10.1056/NEJMoa1811744
    OpenUrlCrossRefPubMed
  4. ↵
    1. Chen TK,
    2. Knicely DH,
    3. Grams ME
    . Chronic kidney disease diagnosis and management: a review. JAMA 2019; 322(13):1294–1304. doi:10.1001/jama.2019.14745
    OpenUrlCrossRefPubMed
  5. ↵
    1. Delgado-Lista J,
    2. Alcala-Diaz JF,
    3. Torres-Peña JD, et al
    . Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 2022; 399(10338):1876–1885. doi:10.1016/S0140-6736(22)00122-2
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 91 (3)
Cleveland Clinic Journal of Medicine
Vol. 91, Issue 3
1 Mar 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Reply: 2023 Update in ambulatory general internal medicine
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In Reply: 2023 Update in ambulatory general internal medicine
Jason T. Alexander, Simran K. Singh, Sachin D. Shah, Brianna Lambert, Jeremy P. Smith
Cleveland Clinic Journal of Medicine Mar 2024, 91 (3) 146; DOI: 10.3949/ccjm.91c.03002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In Reply: 2023 Update in ambulatory general internal medicine
Jason T. Alexander, Simran K. Singh, Sachin D. Shah, Brianna Lambert, Jeremy P. Smith
Cleveland Clinic Journal of Medicine Mar 2024, 91 (3) 146; DOI: 10.3949/ccjm.91c.03002
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • In Reply: In defense of the anion gap
  • In defense of the anion gap
  • Effective but inaccessible antiobesity medications
Show more Letters to the editor

Similar Articles

Subjects

  • Cardiology
  • Endocrinology
  • Nephrology
  • Preventive Care

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire